Investor Relations

Zenabis Presentation

Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations Investor Relations

Zenabis Management Circular

Download Presentation
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

Press Releases

Zenabis Announces Increase in Licensed Capacity by More Than 30% and Provides Date for Next Operational Update

Monday May 13, 2019
Zenabis Announces Increase in Licensed Capacity by More Than 30% and Provides Date for Next Operational Update Vancouver, British Columbia – May…
Read More

Zenabis Announces Grant of Stock Options

Thursday May 2, 2019
Zenabis Announces Grant of Stock Options /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER,…
Read More

Zenabis Provides Operational and Corporate Updates and Files Sun Pharm Investments Ltd. Year End Financial Statements on SEDAR

Monday April 29, 2019
Zenabis Provides Operational and Corporate Updates and Files Sun Pharm Investments Ltd. Year End Financial Statements on SEDAR   Vancouver, British Columbia…
Read More

Zenabis Partners with Farmako to Supply Mass Produced CBD Isolate in Canada and Medical Cannabis to Germany

Monday April 29, 2019
Zenabis Partners with Farmako to Supply Mass Produced CBD Isolate in Canada and Medical Cannabis to Germany   VANCOUVER, BC, April 29,…
Read More

Zenabis Expands Recreational Cannabis Product Offerings in Key Domestic Markets

Tuesday April 23, 2019
Zenabis Expands Recreational Cannabis Product Offerings in Key Domestic Markets   /NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION…
Read More

Zenabis Conditionally Approved to Graduate to the Toronto Stock Exchange

Monday April 22, 2019
Zenabis Conditionally Approved to Graduate to the Toronto Stock Exchange   VANCOUVER, BC, April 22, 2019 – Zenabis Global Inc. (TSXV:ZENA) (“Zenabis”…
Read More

IRS Form 8937 (US Investor Tax Information)

Issuers of corporate securities are required to complete Internal Revenue Service Form 8937 to report organizational actions, including distributions and reorganizations that affect the basis of the securities involved in the organizational action. The tax information contained herein is provided for informational purposes only and should not be construed as legal or tax advice. Zenabis does not provide legal or tax advice. Please consult your personal tax advisor for assistance as to how this information will impact your specific tax situation.

Download Form

Board Policies

The high standards expected of Zenabis Global Inc., officers, and directors are put in place by the Board of Directors and reflect their core values regarding sound corporate governance. Most prominently reflected in them is an understanding of how the fiduciary responsibility the Company has to shareholders receives as much emphasis as the effective and forward-thinking management of company business. The following guidelines details standards and procedures that are in line with this dual-focus approach to operating the company catering to both interests equally. Do note that they may be amended when and as necessary based on the Company's interests or to be in accordance with applicable laws and regulations.

GET THE CORPORATE NEWSLETTER

Want to keep in touch? We'll send you our latest updates. You can unsubscribe at any time.

Consent